



PRESS RELEASE

An Extraordinary Shareholders' Meeting of Pierrel S.p.A. has been called for 25 July 2022 in single call to resolve on the merger by incorporation of Pierrel Pharma S.r.l. with sole shareholder with Pierrel S.p.A.

Publication of documentation for the Shareholders' Meeting of Pierrel S.p.A. convened in extraordinary session on 25 July 2022, in a single convocation

Capua, 23 June 2022 – Pierrel S.p.A. ("**Pierrel**" or the "**Company**") announces that today the Chairman of the Board of Directors of the Company, in execution of the powers granted by the Board of Directors of the Company last 15 June has called the Shareholders' Meeting of Pierrel, in extraordinary session, for 25 July 2022, in single call, to discuss and resolve on the approval of the merger plan of Pierrel Pharma S.r.l. with sole shareholder in Pierrel (the "**Merger project**"). It is expected that the extraordinary shareholders' meeting of Pierrel Pharma S.r.l. with sole shareholder to deliberate on the Merger Plan will also be held on 25 July. The Merger Plan has already been approved by the boards of directors of the Company and of Pierrel Pharma S.r.l. with sole shareholder on 15 June 2022 (for more information, see the press release published by the Company on 15 June 2022 and available on the Company's website at www.pierrelgroup.com, News & Press / Press Releases section).

Furthermore, also today, the following documents have been made available to the public at the registered office, on the Company's website at www.pierrelgroup.com in the section "Investors Relations / Corporate Governance / Shareholders' Meetings Documentation / Shareholders' Meeting of the 25 July 2022" and at the authorized storage mechanism eMarket Storage (www.emarketstorage.com):

- (i) the notice of convocation of the Pierrel Shareholders' Meeting, convened in extraordinary session, in single call, for 25 July 2022, at 10:30, at the Notary's Office Roberto Battista in Via Chiatamone 57, Naples, called to discuss and resolve on the following Agenda:

1. Approval of the plan for the merger by incorporation of Pierrel Pharma S.r.l. with sole shareholder in Pierrel S.p.A. Resolutions pertaining thereto and resulting therefrom.

An extract of the aforementioned call notice is also published today, in accordance with the applicable legislation, in the newspaper "Il Giornale" and on the Company's website at www.pierrelgroup.com, in the "Investor Relations / Governance Documents / Documentation for Shareholders / Shareholders' Meetings Documentation";

- (ii) the report drawn up by the Board of Directors of the Company pursuant to Article 125-ter of the TUF on the agenda of the Extraordinary Shareholders' Meeting and the related resolution proposals; and
- (iii) the delegation forms to the representative designated by the company pursuant to art. 135-undecies and 135-novies of the TUF.

The additional documentation relating to the Extraordinary Shareholders' Meeting of the Company has already been made available to the public in the manner and within the terms provided for by the legislation, including regulations, in force and is available to the public on the Company's website at www.pierrelgroup.com, in the section "Investor Relations / Governance Documents / Documentation for shareholders / Documentation of Shareholders' Meetings".

* * *

Pierrel S.p.A. specialises in the pharmaceutical production (Contract Manufacturing Division) and the development, registration and licensing of new drugs and medical devices (Pharma Division).

Pierrel Group is listed on the EXM exchange which is organised and managed by Borsa Italiana and boasts over 70 years' experience in the pharmaceutical sector, being one of Europe's leading producers of local and dental anaesthetics.



Pierrel also has a production unit in Capua, close to Naples, Italy, that has been authorised by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) for the aseptic production of injectable medicines.

The subsidiary Pierrel Pharma S.r.l. has registered and distributes the Orabloc® dental anaesthetic in Canada, US, Russia and Europe. The registered office of Pierrel S.p.A. is in Capua (CE), Italy.

For further information:

Pierrel S.p.A.

Investor Relator

Mr Fulvio Citaredo

E-mail: investor.relations@pierrelgroup.com

tel. +39 0823 626 111

fax +39 0823 626 228

Spriano Communication & Partners S.r.l.

Media Relations

Cristina Tronconi

E-mail: ctronconi@sprianocommunication.com

tel. +39 333 3460477901

Jacopo Ghirardi

E-mail: ctronconi@sprianocommunication.com

Tel. +39 333 7139257